Press Release
May 25, 2023

ReNAgade Therapeutics Launches With Over $300 Million in Series A Financing

The Life Sciences team advised ReNAgade Therapeutics on its $300 million Series A financing round led by MPM BioImpact and F2 Ventures.

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body.

The Goodwin team was led by Danielle Lauzon, Gabriela Morales-Rivera, Jesse Fishman, Martha Schreck, Evan De Ycaza and Dan Karelitz.

For more details, read the press release and article in Fierce Biotech.